PURPOSE: To investigate the effect of changes in retinal morphology on contrast sensitivity and reading ability in patients with neovascular age-related macular degeneration (AMD) in the Avastin (bevacizumab; Genentech, South San Francisco, CA) for choroidal neovascularization (ABC) Trial. METHODS: Contrast sensitivity obtained with Pelli-Robson charts, reading ability assessed with Minnesota Reading charts, and Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) obtained by protocol refraction, were recorded. Raw Stratus optical coherence tomography (OCT; Carl Zeiss Meditec, Inc., Dublin, CA) images were analyzed with the publicly available software OCTOR, which allows precise delineation of any retinal compartment of interest. Thickness and volume were calculated for neurosensory retina, subretinal fluid (SRF), subretinal tissue, and pigment epithelium detachment, and the resulting measurements were correlated with each visual function parameter. RESULTS:One hundred twenty-two patients with newly diagnosed neovascular AMD and enrolled in the ABC Trial, were evaluated. Increased subretinal tissue volume correlated with decreased contrast sensitivity (Pearson's correlation coefficient, r = -0.4944, P = 0.001). A modest correlation was detected between SRF volume and contrast sensitivity (r = -0.2562, P = 0.004). Increased retinal thickness at the foveal center also correlated with decreased visual function (ETDRS VA: r = -0.4530, P < 0.001). CONCLUSIONS: The strongest correlation detected between the functional parameters assessed and any of the OCT-derived morphologic parameters was that between decreased contrast sensitivity and increased subretinal tissue. In the future, assessment of contrast sensitivity and reading ability, in combination with quantitative subanalysis of retinal compartments, may lead to the identification of parameters relevant to functional improvement and ultimate prognosis in patients with newly diagnosed neovascular AMD (www.controlled-trials.com number, ISRCTN83325075).
RCT Entities:
PURPOSE: To investigate the effect of changes in retinal morphology on contrast sensitivity and reading ability in patients with neovascular age-related macular degeneration (AMD) in the Avastin (bevacizumab; Genentech, South San Francisco, CA) for choroidal neovascularization (ABC) Trial. METHODS: Contrast sensitivity obtained with Pelli-Robson charts, reading ability assessed with Minnesota Reading charts, and Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) obtained by protocol refraction, were recorded. Raw Stratus optical coherence tomography (OCT; Carl Zeiss Meditec, Inc., Dublin, CA) images were analyzed with the publicly available software OCTOR, which allows precise delineation of any retinal compartment of interest. Thickness and volume were calculated for neurosensory retina, subretinal fluid (SRF), subretinal tissue, and pigment epithelium detachment, and the resulting measurements were correlated with each visual function parameter. RESULTS: One hundred twenty-two patients with newly diagnosed neovascular AMD and enrolled in the ABC Trial, were evaluated. Increased subretinal tissue volume correlated with decreased contrast sensitivity (Pearson's correlation coefficient, r = -0.4944, P = 0.001). A modest correlation was detected between SRF volume and contrast sensitivity (r = -0.2562, P = 0.004). Increased retinal thickness at the foveal center also correlated with decreased visual function (ETDRS VA: r = -0.4530, P < 0.001). CONCLUSIONS: The strongest correlation detected between the functional parameters assessed and any of the OCT-derived morphologic parameters was that between decreased contrast sensitivity and increased subretinal tissue. In the future, assessment of contrast sensitivity and reading ability, in combination with quantitative subanalysis of retinal compartments, may lead to the identification of parameters relevant to functional improvement and ultimate prognosis in patients with newly diagnosed neovascular AMD (www.controlled-trials.com number, ISRCTN83325075).
Authors: D Pauleikhoff; D Löffert; G Spital; M Radermacher; J Dohrmann; A Lommatzsch; A C Bird Journal: Graefes Arch Clin Exp Ophthalmol Date: 2002-06-25 Impact factor: 3.117
Authors: Geeta A Lalwani; Philip J Rosenfeld; Anne E Fung; Sander R Dubovy; Stephen Michels; William Feuer; Janet L Davis; Harry W Flynn; Maria Esquiabro Journal: Am J Ophthalmol Date: 2009-04-18 Impact factor: 5.258
Authors: Merina Thomas; Rebecca F Silverman; Filippos Vingopoulos; Megan Kasetty; Gina Yu; Esther L Kim; Amro A Omari; Katherine A Joltikov; Eun Y Choi; Leo A Kim; David N Zacks; John B Miller Journal: J Vitreoretin Dis Date: 2020-11-05
Authors: Pearse A Keane; Florian M Heussen; Yanling Ouyang; Nils Mokwa; Alexander C Walsh; Adnan Tufail; Srinivas R Sadda; Praveen J Patel Journal: Invest Ophthalmol Vis Sci Date: 2012-03-09 Impact factor: 4.799
Authors: Justis P Ehlers; Robert Zahid; Peter K Kaiser; Jeffrey S Heier; David M Brown; Xiangyi Meng; Jamie Reese; Thuy K Le; Leina Lunasco; Ming Hu; Sunil K Srivastava Journal: Ophthalmol Retina Date: 2021-02-26
Authors: Rituparna Ghoshal; Sharanjeet Sharanjeet-Kaur; Norliza Mohamad Fadzil; Haliza Abdul Mutalib; Somnath Ghosh; Nor Fariza Ngah; Roslin Azni Abd Aziz Journal: Int J Environ Res Public Health Date: 2020-09-02 Impact factor: 3.390
Authors: Rituparna Ghoshal; Sharanjeet Sharanjeet-Kaur; Norliza Mohamad Fadzil; Somnath Ghosh; NorFariza Ngah; Roslin Azni Abd Aziz Journal: Int J Environ Res Public Health Date: 2021-05-18 Impact factor: 3.390